Список литературы

"Клинические рекомендации "Острый лимфобластный лейкоз" (утв. Минздравом России)

Список литературы

1. Pui C.-H. Treatment of acute leukemias. New directions for clinical research. New Jersey, Humana Press Inc., 2003.

2. Rabin K.R., Gramatges M.M., Margolin J.F. Acute lymphoblastic leukemia//Principles and Practice of Pediatric Oncology, 7th ed. 2015. P. 463 - 497.

3. Мякова Н.В. Острый лимфобластный лейкоз.//Практическое руководство по детским болезням. Под ред. Коколиной В.Ф., Румянцева А.Г., Том IV - Гематология/онкология детского возраста. Под ред. А.Г. Румянцева, Е.В. Самочатовой. М, Медпрактика-М. 2004. P. 518 - 537.

4. Карачунский А.И., Мякова Н.В. Острый лимфобластный лейкоз//Педиатрия: национальное руководство в 2 т. М, ГЭОТАР-Медиа. 2009. P. 944 - 955.

5. Hunger S.P., Mullighan C.G. Acute lymphoblastic leukemia in children//New England Journal of Medicine. Massachussetts Medical Society, 2015. Vol. 373, N 16. P. 1541 - 1552.

6. Cooper S.L., Brown P.A. Treatment of pediatric acute lymphoblastic leukemia//Pediatric Clinics of North America. W.B. Saunders, 2015. Vol. 62, N 1. P. 61 - 73.

7. Heerema-McKenney A., Cleary M., Arber D. Pathology and molecular diagnosis of leukemias and lymphomas//Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins. 2015. P. 113 - 130.

8. Wenzinger C., Williams E., Gru A.A. Updates in the pathology of precursor lymphoid neoplasms//The revised Fourth edition of the WHO Classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep. 2018. P. 275 - 288.

9. Wang S., He G. 2016 Revision to the WHO classification of acute lymphoblastic leukemia//J. Transl. Intern. Med. Walter de Gruyter GmbH, 2017. Vol. 4, N 4. P. 147 - 149.

10. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC)/ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

11. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).//Leukemia. 1995. Vol. 9, N 10. P. 1783 - 1786.

12. Coustan-Smith E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia//Lancet Oncol. 2009. Vol. 10, N 2. P. 147 - 156.

13. Новикова И.А. et al. Стандарт российско-белорусской кооперативной группы по иммунофенотипированию острого лимфобластного лейкоза у детей//Онкогематология. 2018. Vol. 13(1). P. 73 - 82.

14. Dworzak M.N. et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia//Cytom. Part B - Clin. Cytom. John Wiley and Sons Inc., 2018. Vol. 94, N 1. P. 82 - 93.

15. Литвинов Д.В. et al. Лечение острого лимфобластного лейкоза у детей: современные возможности и нерешенные проблемы//Доктор.Ру. 2015. Vol. 10(111). P. 30 - 37.

16. Pui C.H. Toward a total cure for acute lymphoblastic leukemia//Journal of Clinical Oncology. 2009. Vol. 27, N 31. P. 5121 - 5123.

17. Vrooman L.M., Silverman L.B. Childhood acute lymphoblastic leukemia: Update on prognostic factors//Current Opinion in Pediatrics. 2009. Vol. 21, N 1. P. 1 - 8.

18. Hunger S.P. et al. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7 - 9, 2011//Pediatr. Blood Cancer. 2013. Vol. 60, N 2. P. 344 - 348.

19. B. et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: Significance of low leukocyte counts with blasts or traumatic lumbar puncture//J. Clin. Oncol. 2003. Vol. 21, N 2. P. 184 - 188.

20. Румянцев А.Г., Масчан А.А., Самочатова Е.В. Сопроводительная терапия и контроль инфекций при гематологических и онкологических заболеваниях. 2009. 448 p.

21. Nellis M.E., Goel R., Karam O. Transfusion Management in Pediatric Oncology Patients//Hematology/Oncology Clinics of North America. W.B. Saunders, 2019. Vol. 33, N 5. P. 903 - 913.

22. Schultz K.R. et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)//Blood. 2007. Vol. 109, N 3. P. 926 - 935.

23. Gaynon P.S. et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review.//Cancer. 1997. Vol. 80, N 9. P. 1717 - 1726.

24. Gao J., Liu W.J. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: A meta-analysis//Eur. Rev. Med. Pharmacol. Sci. 2018. Vol. 22, N 22. P. 7858 - 7866.

25. Soverini S., Bassan R., Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: Recent advances and remaining challenges//Journal of Hematology and Oncology. BioMed Central Ltd., 2019. Vol. 12, N 1. P. 1 - 14.

26. J., N., I. Philadelphia-positive B-cell acute lymphoblastic leukemia is initiated in an uncommitted progenitor cell//Leukemia and Lymphoma. Harwood Academic Publishers GmbH, 2001. Vol. 42, N 4. P. 569 - 576.

27. Wu J. et al. [Identification of gene rearrangements in childhood leukemia by using a multiplex polymerase chain reaction-microarray approach].//Zhongguo shi yan xue ye xue za zhi. 2009. Vol. 17, N 4. P. 908 - 912.

28. Borowitz M.J. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study//Blood. 2008. Vol. 111, N 12. P. 5477 - 5485.

29. Conter V. et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study//Blood. 2010. Vol. 115, N 16. P. 3206 - 3214.

30. Schrappe M. et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study//Blood. 2011. Vol. 118, N 8. P. 2077 - 2084.

31. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей//Педиатрия. 2016. Vol. 95(4). P. 11 - 22.

32. Румянцева Ю.В., Карачунский А.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России//Педиатрия. 2009. Vol. 87(4). P. 19 - 28.

33. Sramkova L. et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia//Pediatr. Blood Cancer. 2007. Vol. 48, N 1. P. 93 - 100.

34. Shen Z. et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis//BMC Cancer. 2018. Vol. 18, N 1. P. 755.

35. Sanchez-Garcia J. et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL//Bone Marrow Transplant. 2013. Vol. 48, N 3. P. 396 - 402.

36. McCarville M.B. Malignant pulmonary and mediastinal tumors in children: Differential diagnoses//Cancer Imaging. BioMed Central, 2010. Vol. 10, N SPEC. ISS. A. P. S35.

37. Balduzzi A. et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: Comparison by genetic randomisation in an international prospective study//Lancet. 2005. Vol. 366, N 9486. P. 635 - 642.

38. Schrauder A. et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: Results from ALL-BFM 90 and 95//J. Clin. Oncol. 2006. Vol. 24, N 36. P. 5742 - 5749.

39. Ribera J.M. et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 trial//J. Clin. Oncol. 2007. Vol. 25, N 1. P. 16 - 24.

40. Duval M. et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure//J. Clin. Oncol. 2010. Vol. 28, N 23. P. 3730 - 3738.

41. Румянцева Ю.В. et al. Профилактика нейролейкемии у детей с острым лимфобластным лейкозом: стратегия Москва - Берлин//Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2009. Vol. 8 (2). P. 5 - 14.

42. Pui C.H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment.//Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2006. P. 142 - 146.

43. Pui C.H., Evans W.E. A 50-year journey to cure childhood acute lymphoblastic leukemia//Semin. Hematol. 2013. Vol. 50, N 3. P. 185 - 196.

44. Карачунский А.И. et al. ALL-MB 2015. Протокол кооперативной группы Москва - Берлин по исследованию острого лимфобластного лейкоза у детей. Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева. Версия 10.10.2015 [Electronic resource]. 2015. P. 244. URL: http://www.fnkc.ru/docs/ALLMB2015.pdf.

45. Stary J. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002//J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, N 3. P. 174 - 184.

46. Karachunskiy A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia//Leukemia. Nature Publishing Group, 2008. Vol. 22, N 6. P. 1144 - 1153.

47. Румянцева Ю.В. et al. Эффективность протокола ALL-MB-2002 у детей с острым лимфобластным лейкозом//Терапевтический архив. 2010. Vol. 7. P. 11 - 20.

48. A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000//Leukemia. 2010. Vol. 24, N 2. P. 265 - 284.

49. Фукс О.Ю. et al. Ранний ответ на терапию при использовании ПЭГ-аспарагиназы в циторедуктивной фазе лечения острого лимфобластного лейкоза//Гематология и траснфузиология. 2007. Vol. 52(6). P. 22 - 26.

50. Kumar K. et al. L-asparaginase: An effective agent in the treatment of acute lymphoblastic leukemia//Leukemia and Lymphoma. Informa Healthcare, 2014. Vol. 55, N 2. P. 256 - 262.

51. Schrappe M. et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia//N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 366, N 15. P. 1371 - 1381.

52. Richards S. et al. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. [Review][Erratum appears in Pediatr Blood Cancer. 2013 Oct;60(10): 1729 Note: Attarbarschi, A [corrected to Atta//Pediatr. Blood Cancer. Vol. 60, N 2. P. 185 - 195.

53. Pui C.-H., Howard S.C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia//Lancet Oncol. 2008. Vol. 9, N 3. P. 257 - 268.

54. Pui C.H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation//N. Engl. J. Med. Massachussetts Medical Society, 2009. Vol. 360, N 26. P. 2730 - 2741.

55. Джаныбекова И.А. Интратекальная терапия при острой лимфобластной лейкемии и нейролейкемии у детей//Научные результаты биомедицинских исследований. 2017. Vol. 3, N 3. P. 18 - 30.

56. Pui C.-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia.//J. Clin. Oncol. 2003. Vol. 21, N 2. P. 179 - 181.

57. Leoni V., Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia//Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, N 3. P. 295.

58. Bernt K.M., Hunger S.P. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia//Frontiers in Oncology. Frontiers Research Foundation, 2014. Vol. 4 MAR.

59. Schultz K.R., Bowman W.P., Aledo A. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome-positive (Phю) acute lymphoblastic leukemia (ALL) with longer term follow up: Updated Results of Children's Oncology Group (COG)//Pediatr. Blood Cancer. 2010. Vol. 54. P. 788.

60. Schultz K.R. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031//Leukemia. Nature Publishing Group, 2014. Vol. 28, N 7. P. 1467 - 1471.

61. Short N.J. et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?//Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd, 2017. Vol. 30, N 3. P. 193 - 200.

62. Biondi A. et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial//Lancet Haematol. Elsevier Ltd, 2018. Vol. 5, N 12. P. e641 - e652.

63. Shen S. et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial//JAMA Oncology. American Medical Association, 2019. Vol. 6, N 3. P. 358 - 366.

64. Hijiya N. et al. Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia//Clin. Cancer Res. American Association for Cancer Research Inc., 2020. Vol. 26, N 4. P. 812 - 820.

65. Porkka K. et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia//Blood. American Society of Hematology, 2008. Vol. 112, N 4. P. 1005 - 1012.

66. Chiaretti S., Messina M., R. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?//Cancer. John Wiley and Sons Inc., 2019. Vol. 125, N 2. P. 194 - 204.

67. Khan M., Siddiqi R., Tran T.H. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options//Seminars in Hematology. W.B. Saunders, 2018. Vol. 55, N 4. P. 235 - 241.

68. Roberts K.G. Why and how to treat Ph-like ALL?//Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd, 2018. Vol. 31, N 4. P. 351 - 356.

69. Kotb A. et al. Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives//Experimental Hematology. Elsevier Inc., 2018. Vol. 67. P. 1 - 9.

70. Pui C.H. et al. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia//Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc., 2017. Vol. 17, N 8. P. 464 - 470.

71. Ding Y.Y. et al. Clinical efficacy of ruxolitinib and chemotherapy in a child with philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure//Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 9. P. e427 - e431.

72. Richards S. et al. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12 000 randomised children//Lancet. 1996. Vol. 347. P. 1783 - 1788.

73. Schmiegelow K. et al. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: Clinical facts and fiction//Journal of Pediatric Hematology/Oncology. Lippincott Williams and Wilkins, 2014. Vol. 36, N 7. P. 503 - 517.

74. Yetgin S. et al. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children//Br. J. Haematol. Blackwell Publishing Ltd, 2010. Vol. 149, N 5. P. 722 - 733.

75. Nagatoshi Y. et al. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia//Pediatr. Blood Cancer. 2010. Vol. 55, N 2. P. 239 - 247.

76. Shukla N. et al. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia//Pediatr. Blood Cancer. 2014. Vol. 61, N 3. P. 431 - 435.

77. Miano M. et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients//Leuk. Lymphoma. 2012. Vol. 53, N 9. P. 1693 - 1698.

78. Gossai N. et al. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD)//Bone Marrow Transplant. 2014. Vol. 49, N 3. P. 440 - 442.

79. Liu A.P. et al. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide//Ann Hematol. 2016. Vol. 95(3). P. 501 - 507.

80. Patrick K., Vora A. Update on biology and treatment of T-cell acute lymphoblastic leukaemia//Current Opinion in Pediatrics. Lippincott Williams and Wilkins, 2015. Vol. 27, N 1. P. 44 - 49.

81. Winter S.S. et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology group Study AALL0434//Pediatr. Blood Cancer. John Wiley and Sons Inc., 2015. Vol. 62, N 7. P. 1176 - 1183.

82. Hefazi M., Litzow M.R. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia//Current Hematologic Malignancy Reports. Current Science Inc., 2018. Vol. 13, N 4. P. 265 - 274.

83. Zwaan C.M. et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study//Br. J. Haematol. 2017. Vol. 179, N 2. P. 284 - 293.

84. Dunsmore K.P. et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group//J. Clin. Oncol. 2012. Vol. 30, N 22. P. 2753 - 2759.

85. Ribera J.M. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia//Expert Review of Hematology. Taylor and Francis Ltd, 2017. Vol. 10, N 12. P. 1057 - 1067.

86. Algeri M. et al. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia//Expert Review of Hematology. Taylor and Francis Ltd, 2018. Vol. 11, N 12. P. 945 - 956.

87. Von Stackelberg A. et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia//J. Clin. Oncol. American Society of Clinical Oncology, 2016. Vol. 34, N 36. P. 4381 - 4389.

88. Yu J., Wang W., Huang H. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis//Hematology. NLM (Medline), 2019. Vol. 24, N 1. P. 199 - 207.

89. Coiffier B. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review//Journal of Clinical Oncology. 2008. Vol. 26, N 16. P. 2767 - 2778.

90. Cairo M.S. et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus//Br. J. Haematol. 2010. Vol. 149, N 4. P. 578 - 586.

91. Agrawal A.K., Chang P.P., Feusner J. Twice weekly pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia//J. Pediatr. Hematol. Oncol. 2011. Vol. 33, N 1.

92. H. et al. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia//Dan. Med. Bull. 2001. Vol. 48, N 4. P. 275 - 277.

93. Stern A. et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients//Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2014. Vol. 2014, N 10. P. CD005590.

94. Lehrnbecher T. et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update//Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, N 18. P. 2082 - 2094.

95. Pui C.H. et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia//N. Engl. J. Med. 1997. Vol. 336, N 25. P. 1781 - 1787.

96. Kaya Z., Belen F.B., N. Granulocyte Colony Stimulating Factor Induced Sweet's Syndrome Following Autologous Transplantation in a Child with Relapsed Acute Myeloblastic Leukemia//Indian J. Hematol. Blood Transfus. Springer India, 2014. Vol. 30, N Suppl 1. P. 376 - 378.

97. Hill F.G.H. et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172)//Br. J. Haematol. 2004. Vol. 124, N 1. P. 33 - 46.

98. Kelly M.J. et al. Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: A systematic review and meta-analysis//American Journal of Hematology. Wiley-Liss Inc., 2014. Vol. 89, N 10. P. 992 - 997.

99. Vora A. et al. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy//J. Clin. Oncol. American Society of Clinical Oncology, 2016. Vol. 34, N 9. P. 919 - 926.

100. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

101. European Physical and Rehabilitation Medicine Bodies Alliance. White book on physical and rehabilitation medicine in Europe (3th Edition): Chaper 1: Definition an conceps of PRM//Eur. J. Phys. Rehabil. Med. 2018. Vol. 54, N 2. P. 156 - 165.

102. Angle-Zahn A. Methotrexate for Use in Pediatric Populations//Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. 2008. P. 12.

103. Fleischer G. Sodium methotrexste//Physician Desk Reference: A Concise Drug Guide for Pediatrics. 2007. P. 214 - 215.

104. Harms D.O. et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: Results of the randomized trial COALL-92//Blood. 2003. Vol. 102, N 8. P. 2736 - 2740.

Приложение А1

СОСТАВ РАБОЧЕЙ ГРУППЫ

1. Карачунский А.И. - д.м.н., профессор, директор института онкологии, радиологии и ядерной медицины ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ; профессор кафедры онкологии, гематологии и лучевой терапии п/ф ФГБОУ ВО "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" МЗ РФ; член правления Национального общества детских гематологов и онкологов (НОДГО).

2. Румянцев А.Г. - академик РАН, д.м.н., профессор, Президент ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ; профессор кафедры онкологии, гематологии и лучевой терапии п/ф ФГБОУ ВО "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" МЗ РФ; главный внештатный детский специалист гематолог; Президент Национального общества детских гематологов и онкологов (НОДГО), член правления Союза педиатров России.

3. Румянцева Ю.В. - д.м.н., доцент, зав. отделом исследования лимфопролиферативных заболеваний ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ; профессор кафедры онкологии, гематологии и лучевой терапии п/ф ФГБОУ ВО "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" МЗ РФ; член Национального общества детских гематологов и онкологов (НОДГО).

4. Попов А.М. - к.м.н., зав. лабораторией иммунофенотипирования гемобластозов ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ.

5. Ольшанская Ю.В. - к.м.н., зав. лабораторией цитогенетики и молекулярной генетики ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ.

6. Стефанов Д.Н. - научный сотрудник, зав. научно-организационным отделом ФГБУ "Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева" МЗ РФ, член Российского общества онкогематологов

Конфликт интересов отсутствует.

Приложение А2

МЕТОДОЛОГИЯ РАЗРАБОТКИ КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ